Market Research Logo

Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Industry Analysis & Outlook (2017-2026)

1. Market Overview
1.1 Nonalcoholic Steatohepatitis (NASH)
Table 1: Spectrum of Non-alcoholic Fatty Liver Disease (NAFLD)
1.2 Causes & Symptoms
1.3 Diagnosis
Table 2: Methods for NASH Diagnosis
1.4 Treatment
Table 3: Off Label Therapies for NASH (2016)
Table 4: Potential Phase III Drug Candidates
2. Global NASH Market
2.1 Global NASH Drugs Market Forecast by Value
Table 5: Global NASH Drugs Market Forecast by Value (2017-2026)
2.2 Global NASH Drugs Market Forecast by Drug Class
Table 6: Global NASH Drugs Market Forecast by Drug Class (2017/2021/2026)
2.3 Global NASH Off Label Drugs Market Forecast by Value
Table 7: Global NASH Off Label Drugs Market Forecast by Value (2017-2026)
3. Global NASH Therapeutics Market
3.1 Global NASH Therapeutics Market Forecast by Value
Table 8: Global NASH Therapeutics Market Forecast by Value (2020-2026)
3.2 Global NASH Therapeutics Market Forecast by Drug Type
Table 9: Global NASH Therapeutics Market Forecast by Drug Type (2021)
Table 10: Global NASH Therapeutics Market Forecast by Drug Type (2026)
3.3 Global NASH Therapeutics Market Forecast by Region
Table 11: Global NASH Therapeutics Market Forecast by Region (2021)
Table 12: Global NASH Therapeutics Market Forecast by Region (2026)
3.4 Global NASH Therapeutics Market by Type
3.4.1 Global Elafibranor Revenue Forecast by Value
Table 13: Global Elafibranor Revenue Forecast by Value (2020-2026)
3.4.2 Global Obeticholic Acid (OCA) Revenue Forecast by Value
Table 14: Global Obeticholic Acid (OCA) Revenue Forecast by Value (2020-2026)
3.4.3 Global Obeticholic Acid (OCA) Revenue Forecast by Region
Table 15: Global Obeticholic Acid (OCA) Revenue Forecast by Region (2026)
3.4.4 Global Cenicriviroc (CVC) Revenue Forecast by Value
Table 16: Global Cenicriviroc (CVC) Revenue Forecast by Value (2020-2026)
3.4.5 Global Cenicriviroc (CVC) Revenue Forecast by Region
Table 17: Global Cenicriviroc (CVC) Revenue Forecast by Region (2026)
3.4.6 Global Aramchol Revenue Forecast by Value
Table 18: Global Aramchol Revenue Forecast by Value (2022-2026)
4. Regional NASH Market
4.1 The US
4.1.1 The US NASH Therapeutics Market Forecast by Value
Table 19: The US NASH Therapeutics Market Forecast by Value (2020-2026)
4.2 The Europe
4.2.1 Europe NASH Therapeutics Market Forecast by Value
Table 20: Europe NASH Therapeutics Market Forecast by Value (2020-2026)
4.3 ROW
4.3.1 ROW NASH Therapeutics Market Forecast by Value
Table 21: ROW NASH Therapeutics Market Forecast by Value (2020-2026)
5. Market Dynamics
5.1 Growth Drivers
5.1.1 Rising Patient Base
Table 22: The US NASH Market by Patient Population (2017-2026)
5.1.2 Increasing Population with Type-2 Diabetes
Table 23: Global Type-2 Diabetes Population Forecast (2017-2026)
5.1.3 Escalating Obese Population
Table 24: Global Obese Population (2012-2016)
5.1.4 Rising Healthcare Expenditure
Table 25: Global Healthcare Expenditure Per Capita (2012-2016)
5.1.5 Increasing GDP Per Capita
Table 26: Global GDP Per Capita (2012-2016)
5.1.6 Vast Unmet Medical Need
5.2 Key Trends & Development
5.2.1 Strong Research & Development Efforts by Companies
Table 27: R&D Expenditure of Companies (2016)
5.2.2 Development of NASH Diagnosis Methods and Biomarkers
Table 28: Selected Diagnosis Methods in Development (2016)
5.3 Challenges
5.3.1 Absence of Low-Priced and Effective Diagnostics
5.3.2 Regulatory Challenges and Undefined Pathogenesis
5.3.3 Costly NASH Therapeutics
6. Competitive Landscape
6.1 Revenue and Market Cap Comparison
Table 29: NASH Key Players- Revenue and Market Cap Comparison (2016)
6.2 Major Pipeline Products
Table 30: Key NASH Therapeutics Under Pipeline (2016)
7. Company Profiles
7.1 Genfit SA
7.1.1 Business Overview
7.1.2 Financial Overview
Table 31: Genfit SA Revenue and Net Loss (2012-2016)
7.1.3 Business Strategies
Table 32: Genfit SA R&D Expenditure (2013-2016)
Table 33: Genfit SA Proprietary Programs (2016)
7.2 Intercept Pharmaceuticals
7.2.1 Business Overview
Table 34: Intercept Pharmaceuticals Products in Pipeline (2016)
7.2.2 Financial Overview
Table 35: Intercept Pharmaceuticals Revenue and Net Income (2012-2016)
7.2.3 Business Strategies
Table 36: Intercept Pharmaceuticals R&D Expenditure (2013-2016)
7.3 Allergan (Tobira)
7.3.1 Business Overview
Table 37: Allergan (Tobira) Revenue by Segment (2016)
7.3.2 Financial Overview
Table 38: Allergan (Tobira) Revenue and Net Loss (2012-2016)
7.3.3 Business Strategies
Table 39: Allergan (Tobira) R&D Expenditure (2013-2016)
Table 40: Allergan (Tobira) Products Under Development for NASH (2016)
7.4 Gilead Sciences
7.4.1 Business Overview
Table 41: Gilead Sciences Revenue by Geographical Region (2016)
7.4.2 Financial Overview
Table 42: Gilead Sciences Revenue and Net Income (2012-2016)
7.4.3 Business Strategies
Table 43: Gilead Sciences R&D Expenditure (2013-2016)

Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Industry Analysis & Outlook (2017-2026)

Non-alcoholic steatohepatitis or NASH is a form of liver disease that causes inflammation and accumulation of fat tissues in the liver. It resembles alcoholic liver disease but occurs to those who drink too little or no alcohol. NASH shows no symptoms and is also known as a “Silent” liver disease. NASH can lead to cirrhosis, in which liver is permanently damaged and scarred and after a certain point, no treatment can cure it and thus lead to death.

There are two types of fatty liver disease: alcoholic fatty liver disease and non-alcoholic fatty liver disease (NAFLD). When inflammation is present with accumulation of fat in the liver then it is referred as NASH. Obesity and diabetes are most common cause of NASH disease. It is a challenge for the patient to recognize the accumulation of fat in the liver as patient experience no such symptoms until reach the advanced stage of the disease. The diagnosis of NASH includes blood tests, MRI, X-rays and liver biopsy. Treatment of NASH includes managing and improving the condition of NASH from being worse and is recommended to bring changes in lifestyle and also use of off label drugs to control and manage indications related to NASH. Currently there is no approved drug in the market but is expected to enter the market in 2020. Currently, there are five potential Phase III drugs in the market including Elafibranor, Ocaliva (OCA), Cenicriviroc (CVC), Selonsertib and Aramchol.

The global NASH market is expected to show significant growth after the introduction of therapeutics drugs in 2020. Growth of market will mainly be driven by increasing patient base, rise in obese population, increasing type-2 diabetic population and increasing health expenditure. However, growth of market will also be hindered by absence of effective diagnostics, costly drugs, regulatory challenges and undefined pathogenesis.

The report “Global NASH Drugs Market: Industry Analysis & Outlook (2017-2026)” analyzes the development of this market, with focus on the US and Europe region. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: Genfit SA, Intercept Pharmaceuticals, Inc., Allergan Plc. (Tobira) and Gilead Sciences are being profiled along with their key financials and strategies for growth. The report contains a comprehensive analysis of the global NASH market along with the study of the regional markets.


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;